Needham lowered the firm’s price target on Crispr Therapeutics to $85 from $88 but keeps a Buy rating on the shares. The potential approval of exa-cel is mostly derisked ahead of the December 8th PDUFA given last week’s favorable advisory committee commentary, the analyst tells investors in a research note. As part of its Q3 results, Crispr also announced preclinical results for CTX310 and CTX320, which will be presented at AHA, and both candidates demonstrated meaningful reductions in genetic drivers of ASCVD, Needham added.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on CRSP:
- Crispr Therapeutics price target lowered to $56 from $64 at Barclays
- Crispr Therapeutics reports Q3 EPS ($1.41), consensus ($1.95)
- CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results
- Crispr Therapeutics options imply 5.7% move in share price post-earnings
- CRISPR Therapeutics Announces Preclinical Data at the American Heart Association (AHA) Scientific Sessions 2023